Published • loading... • Updated
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
Summary by Watauga Democrat
32 Articles
32 Articles
keenesentinel.com+31 Reposted by 31 other sources
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and OrizaProceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis
Coverage Details
Total News Sources32
Leaning Left1Leaning Right4Center11Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
C 69%
R 25%
Factuality
To view factuality data please Upgrade to Premium
